Why Is Lisinopril One of the Worst Blood Pressure Meds?

Lisinopril is not one of the worst blood pressure medications by any broad clinical measure, but it has a reputation problem rooted in real side effects that patients experience more viscerally than with competing drugs. It is, in fact, the single most-prescribed antihypertensive in the United States, accounting for about 78% of all ACE inhibitor fills as of 2021 and peaking at roughly 98 million prescriptions in 2014. That sheer ubiquity means millions of people have encountered its most infamous side effect, a persistent dry cough, along with rarer but more alarming complications. The question people are really asking is less about whether lisinopril is dangerous and more about why a drug that annoys or harms so many patients remains a first-line choice.

The Dry Cough That Drives People to Google

The single biggest reason lisinopril gets called “the worst” is the cough. It is dry, ticklish, unproductive, and it does not go away as long as you keep taking the drug. Estimates vary, but roughly one in ten patients on any ACE inhibitor develops this cough, with some studies reporting rates anywhere from about 2% to 11% depending on how the trial is designed and what population is studied.¹² Among ACE inhibitors specifically, one review that compared cough rates across the class found lisinopril’s placebo-adjusted incidence was about 3.5%, which is actually mid-range; ramipril came in higher at around 12%.² So the cough is not uniquely a lisinopril problem. It belongs to the entire ACE inhibitor class. But because lisinopril dominates ACE inhibitor prescriptions so thoroughly, it shoulders almost all the public blame.

The mechanism behind the cough involves bradykinin. ACE inhibitors block the enzyme that breaks down bradykinin, a molecule that dilates blood vessels. That buildup of bradykinin is partly why these drugs lower blood pressure, but bradykinin also irritates airway nerve endings. The result is a cough that has nothing to do with infection or allergy and everything to do with the drug doing exactly what it was designed to do, just a bit too enthusiastically in the lungs.¹ The cough can start weeks or even months into therapy, which makes patients feel blindsided. Once it develops, the standard fix is to switch to an ARB (angiotensin receptor blocker), which lowers blood pressure through a related but slightly different pathway without the same bradykinin accumulation.

Angioedema Is Rare but Genuinely Frightening

If the cough is the nuisance that drives everyday complaints, angioedema is the complication that drives fear. This is sudden swelling of the lips, tongue, throat, or face, and in the worst cases it can obstruct the airway. Angioedema from ACE inhibitors is uncommon in the general population, but it is unpredictable. It can appear months or even years after a patient starts taking the drug, and there is evidence that some patients develop angioedema for the first time even after discontinuing the medication.³ The same bradykinin mechanism responsible for the cough appears to drive angioedema, and the presence of cough has been identified as a risk factor for going on to develop it.

The angioedema risk is not evenly distributed. Black patients face a substantially higher rate of this side effect. One study found that Black Americans using ACE inhibitors had roughly four and a half times the risk of angioedema compared to white patients, even after accounting for other factors.⁴ Multiple studies have confirmed this disparity: the absolute risk for white patients has been estimated at around 0.3%, compared to about 0.7% for Black patients, with similar gaps found using person-year calculations.⁵ A British pharmacovigilance review reported that 65% of ACE inhibitor-related angioedema cases involved Black or Afro-Caribbean patients, a proportion far exceeding their share of the patient population.⁶ These numbers are part of why current guidelines often steer Black patients toward calcium channel blockers or thiazide diuretics first.

What the ALLHAT Trial Actually Showed

Much of the clinical case against lisinopril as a first-line option traces back to the ALLHAT trial, one of the largest randomized hypertension trials ever conducted. ALLHAT compared lisinopril against chlorthalidone (a thiazide-type diuretic) and amlodipine (a calcium channel blocker) in over 33,000 high-risk patients. The headline finding was that for the primary endpoint of fatal coronary heart disease and nonfatal heart attack, no significant difference emerged between the three drugs. All three performed comparably on that front.⁷

The problems showed up in secondary outcomes. Compared to chlorthalidone, the lisinopril group had a 15% higher risk of stroke, a 10% higher risk of combined cardiovascular disease, a 19% higher risk of heart failure, and about an 11% higher risk of hospitalized or treated angina.⁷ Those gaps look alarming in isolation, but context matters. One likely explanation is that lisinopril simply did not control blood pressure as consistently as the other two drugs in this particular study population, which was older and included a large proportion of Black patients, a group where ACE inhibitors tend to be less effective as monotherapy. A sub-analysis of ALLHAT confirmed that Black patients receiving lisinopril had notably less blood pressure reduction than those on chlorthalidone, with a roughly 5/2 mmHg gap at two years.⁸

A separate ALLHAT analysis found that lisinopril also produced more visit-to-visit blood pressure variability than either chlorthalidone or amlodipine. Patients on lisinopril had a standard deviation of systolic blood pressure about 0.77 mmHg higher than the chlorthalidone group after adjustment, while amlodipine actually lowered variability relative to the diuretic.⁹ Blood pressure that swings more from visit to visit is independently associated with worse cardiovascular outcomes, so this is not a trivial observation. It suggests that for some patients, lisinopril delivers a less steady day-to-day blood pressure profile than alternatives.

Hyperkalemia and Kidney Concerns

ACE inhibitors reduce the kidney’s ability to excrete potassium, which means your blood potassium levels can creep up. For most healthy people, this is clinically insignificant. But for patients with chronic kidney disease, diabetes, or heart failure, or those who take potassium supplements or potassium-sparing diuretics alongside lisinopril, the risk becomes real. In one study of over 5,000 patients with chronic kidney disease who started lisinopril, about 2.8% developed hyperkalemia within 90 days.¹⁰ Key predictors included reduced kidney function, diabetes, heart failure, and concurrent use of potassium-sparing diuretics.

A separate study found that long-acting ACE inhibitors like lisinopril and enalapril were more frequently associated with hyperkalemia cases than short-acting ones, though the authors noted this could partly reflect their far greater prescribing volume.¹¹ Potassium monitoring through periodic blood tests is standard practice when prescribing any ACE inhibitor, particularly in patients with kidney issues.

The kidney relationship with lisinopril runs in both directions. ACE inhibitors can cause a temporary rise in serum creatinine (a marker of kidney strain), which occasionally alarms patients who see the number on their lab results. One large study of patients prescribed lisinopril found that about 0.2% experienced a significant creatinine jump, but none of those patients went on to develop end-stage kidney disease, and the rises were typically associated with other factors like dehydration, infection, or heart failure.¹² This is why doctors expect a small creatinine bump when you start the drug and only worry if it rises substantially.

Adding NSAIDs to the mix, which plenty of patients do casually with over-the-counter ibuprofen or naproxen, increases the kidney risk. Both drug classes independently affect kidney blood flow, and in combination they can synergistically compromise renal function. Several cases of reversible kidney failure have been documented with the combination, and the interaction is common enough that clinicians are taught to watch for it.¹³ If you are on lisinopril, regular use of ibuprofen or similar painkillers is something worth discussing with your doctor.

The Pregnancy Risk Is Absolute

Lisinopril and all other ACE inhibitors are strictly contraindicated in pregnancy. The risks to a developing fetus have been known for decades, and the category of harm extends even to first-trimester exposure. A large cohort study found that infants exposed to ACE inhibitors only during the first trimester had roughly 2.7 times the risk of major birth defects compared to unexposed infants, with cardiovascular malformations about 3.7 times more likely and central nervous system defects about 4.4 times more likely.¹⁴ More recent data from a European cardiac disease registry confirmed an elevated odds of congenital anomaly with first-trimester ACE inhibitor use.¹⁵ This is not a “weigh the risks and benefits” situation. Women who are pregnant or planning to become pregnant should not be on lisinopril, and any woman of reproductive age prescribed the drug should be aware of this.

Why Doctors Still Prescribe It So Heavily

Given all of the above, it is reasonable to wonder why lisinopril remains the most prescribed blood pressure medication in the country. The answer is a combination of cost, proven benefits beyond blood pressure, and clinical inertia.

Lisinopril went off patent in 2002, and since then its generic versions have become extraordinarily cheap. It is frequently available for just a few dollars a month, making it accessible to uninsured patients and attractive to formulary committees. A survey of general practitioners found that many prefer starting with ACE inhibitors for younger patients without complications, citing their kidney-protective properties and manageable side-effect profile, and typically reserve ARBs for patients who develop problems like the cough.¹⁶ After patent exclusivity ended, lisinopril’s prescribing volume climbed steeply, peaking at roughly 98 million fills in 2014.¹⁷

The clinical benefits are also genuine. In patients who have just suffered a heart attack, the GISSI-3 trial of over 19,000 patients showed that lisinopril given within 24 hours of symptom onset and continued for six weeks reduced the risk of death by about 11% and reduced a combined endpoint of death plus severe heart dysfunction by roughly 8%.¹⁸ The survival benefit appeared within one to two days and persisted even after the drug was stopped. For kidney protection in diabetes, lisinopril has shown an ability to reduce protein leakage in urine (a marker of kidney damage) and to preserve the microscopic blood vessels in the kidneys that are damaged by high blood sugar.¹⁹²⁰ There is even evidence that lisinopril improves insulin sensitivity in patients with high blood pressure, an effect not shared by all competing drug classes.²¹

These extra benefits mean that for specific patients, particularly those with diabetes, heart failure, or a recent heart attack, lisinopril is not just adequate but may be the best-supported option. The “worst blood pressure med” framing tends to come from people for whom the drug was prescribed purely for uncomplicated high blood pressure, where its advantages over cheaper thiazides or smoother calcium channel blockers are less clear-cut.

Who Should Probably Be on Something Else

The evidence points to several groups where lisinopril is a poor fit, or at least where the conversation with a prescriber should include alternatives upfront:

Black patients: Both blood pressure response and angioedema risk are less favorable. Guidelines generally recommend starting with a calcium channel blocker or thiazide diuretic in this population, either as monotherapy or with an ACE inhibitor added later as part of combination therapy.
Women of reproductive age: The teratogenic risk means any woman who could become pregnant needs a safer alternative, typically a calcium channel blocker like nifedipine or a beta-blocker like labetalol, which are standard in pregnancy.
Patients with chronic kidney disease and high potassium: The hyperkalemia risk escalates substantially. Close monitoring can make it workable, but an ARB or a calcium channel blocker may be simpler.
Anyone who develops the cough: This one sounds obvious, but a surprising number of patients tolerate the cough for months before mentioning it, assuming it is unrelated. If you developed a dry cough within weeks or months of starting lisinopril, tell your prescriber. The switch to an ARB usually resolves it completely.
Heavy NSAID users: People who regularly take ibuprofen, naproxen, or similar anti-inflammatory drugs face compounded kidney risk. If you cannot stop the NSAIDs, a different antihypertensive class is safer for the kidneys.

How ACE Inhibitors Compare to ARBs

The most frequent alternative when lisinopril causes problems is an ARB like losartan, valsartan, or telmisartan. ARBs block the receptor that angiotensin II binds to, rather than blocking the enzyme that creates it. Because they do not cause bradykinin to accumulate, the cough and angioedema rates are drastically lower. For pure blood pressure lowering, the two classes are broadly comparable. In a head-to-head trial, lisinopril reduced systolic blood pressure by about 20 mmHg and losartan by about 17 mmHg, a modest difference that was not statistically significant between the groups.²¹

Where lisinopril showed a potential edge in that trial was insulin sensitivity: patients on lisinopril had a meaningful improvement in how their bodies responded to insulin, while patients on losartan did not. Whether that metabolic advantage translates into long-term diabetes prevention is an open question, but it illustrates why ACE inhibitors retain a niche even when ARBs are better tolerated. For patients who can take lisinopril without side effects, its metabolic and renal benefits may add up to more than just blood pressure control.

The Reputation Problem

Lisinopril’s status as the drug people love to hate has a peculiar self-reinforcing quality. Because it is prescribed so often, a large absolute number of people experience side effects, even if the percentage is modest. Those patients talk to friends, post online, and create a disproportionate impression that lisinopril is unusually problematic. Meanwhile, amlodipine (which causes ankle swelling in a meaningful minority of users) and chlorthalidone (which can trigger gout, low sodium, and potassium depletion) generate fewer complaints partly because fewer people take them, and partly because their side effects are less viscerally annoying than a cough that will not quit.

The ALLHAT results also created a lasting narrative. For years after publication, the trial was cited as evidence that ACE inhibitors should not be first-line therapy, particularly in diverse populations. More recent thinking is somewhat more forgiving: ALLHAT used lisinopril as monotherapy without the option to combine drugs easily, which does not reflect how most patients are treated today. In current practice, patients often take two or three antihypertensives, and an ACE inhibitor paired with a calcium channel blocker or a low-dose diuretic tends to perform better than any single agent alone. The trial was asking whether lisinopril could stand on its own against a diuretic, and the answer, for many patients, was no. That does not mean it has no place in a combination regimen.

Your genetics also play a role that gets underappreciated. The bradykinin pathway that produces the cough and angioedema is influenced by polymorphisms in genes encoding the ACE enzyme, bradykinin receptors, and related pathways. Some people are simply more susceptible than others, and those susceptibilities do not distribute evenly across ethnic groups.² As pharmacogenomic testing becomes more common, it is possible that prescribers will be able to predict who will tolerate an ACE inhibitor and who should skip straight to an ARB, reducing the trial-and-error that currently frustrates so many patients.